Professor
Mamiko Sakata-Yanagimoto




Advanced Hemato-Oncology

Research keywords

Leukemia

Myelodysplasia



Site content under construction. Please visit again soon.


参考文献


* Co-corresponding author,
+ Co-first author

Makishima K, Suehara Y, Abe Y, Hattori K, Kusakabe M, Matsuoka R, Chiba S, Sakata-Yanagimoto M * . “Intra-tumor heterogeneity of lymphoma identified by multi-region sequencing of autopsy samples.” Cancer Sci. in press.

Nguyen YTM, Fujisawa M, Nguyen TB, Suehara Y, Sakamoto T, Matsuoka R, Abe Y, Fukumoto K, Hattori K, Noguchi M, Matsubara D, Chiba S, Sakata-Yanagimoto M * “Tet2-deficency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model.” Cancer Sci. in press.

Fukumoto K, Sakata-Yanagimoto M *, Fujisawa M, Sakamoto T, Miyoshi H, Suehara Y, Tran B. Nguyen, Suma S, Yanagimoto S, Shiraishi Y, Chiba K, Bouska A, Kataoka K, Ogawa S, Iqbal J, Ohshima K, Chiba S. “VAV1 mutations contribute to development of T-cell neoplasms in mice.” Blood. 136(26):3018-3032, 2020.

Shrestha R, Sakata-Yanagimoto M *, Maie K, Oshima M, Ishihara M, Suehara Y, Fukumoto K, Nakajima-Takagi Y, Matsui H, Kato T, Muto H, Sakamoto T, Kusakabe M, Nannya Y, Makishima H, Ueno H, Saiki R, Ogawa S, Chiba K, Shiraishi Y, Miyano S, Mouly E, Bernard OA, Inaba T, Koseki H, Iwama A, Chiba S. “Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status.” Blood Adv. 4(5):845-854, 2020.

Nguyen TB, Sakata-Yanagimoto M +*, Fujisawa M, Nuhat ST, Miyoshi H, Nannya Y, Hashimoto K, Fukumoto K, Bernard OA, Kiyoki Y, Ishitsuka K, Momose H, Sukegawa S, Shinagawa A, Suyama T, Sato Y, Nishikii H, Obara N, Kusakabe M, Yanagimoto S, Ogawa S, Ohshima K, Chiba S. “Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma.” Cancer Res. 80(9):1875-1884, 2020.

Suehara Y, Sakata-Yanagimoto M, Hattori K, Kusakabe M, Nanmoku T, Sato T, Noguchi M, Chiba S. “Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.” Cancer Sci. 110(10):3375-3381, 2019.

Hattori K, Sakata-Yanagimoto M *, Kusakabe M, Nanmoku T, Suehara Y, Matsuoka R, Noguchi M, Yokoyama Y, Kato T, Kurita N, Nishikii H, Obara N, Takano S, Ishikawa E, Matsumura A, Muratani M, Hasegawa Y, Chiba S. “Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.” Cancer Sci. 110(1):401-407, 2019.

Tanzima Nuhat S, Sakata-Yanagimoto M *, Komori D, Hattori K, Suehara Y, Fukumoto K, Fujisawa M, Kusakabe M, Matsue K, Wakamatsu H, Shimadzu M, Chiba S. “Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma.” Cancer Sci. 109(5):1682-1689, 2018.

Suehara Y, Sakata-Yanagimoto M, Hattori K, Nanmoku T, Itoh T, Kaji D, Yamamoto G, Abe Y, Narita K, Takeuchi M, Matsue K, Sato T, Noguchi M, Baba N, Sakamoto T, Kusakabe M, Kurita N, Kato T, Yokoyama Y, Nishikii H, Obara N, Hasegawa Y, Chiba S. “Liquid biopsy for the identification of intravascular large B-cell lymphoma.” Haematologica. 103(6):e241-e244, 2018.

Hattori K, Sakata-Yanagimoto M *, Suehara Y, Yokoyama Y, Kato T, Kurita N, Nishikii H, Obara N, Takano S, Ishikawa E, Matsumura A, Hasegawa Y, Chiba S. “Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.” Cancer Sci. 109(1):225-230, 2018.

Fujisawa M, Sakata-Yanagimoto M +*, Nishizawa S, Komori D, Gershon P, Kiryu M, Tanzima S, Fukumoto K, Enami T, Muratani M, Yoshida K, Ogawa S, Matsue K, Nakamura N, Takeuchi K, Izutsu K, Fujimoto K, Teshima T, Miyoshi H, Gaulard P, Ohshima K, Chiba S. “Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.” Leukemia. 32(3):694-702, 2018.

Nguyen TB, Sakata-Yanagimoto M *, Asabe Y, Matsubara D, Kano J, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Izutsu K, Nakamura N, Takeuchi K, Miyoshi H, Ohshima K, Minowa T, Ogawa S, Noguchi M, Chiba S. “Identification of cell-type-specific mutations in nodal T-cell lymphomas.” Blood Cancer J. 7(1):e516, 2017.

Muto H, Sakata-Yanagimoto M, Nagae G, Shiozawa Y, Miyake Y, Yoshida K, Enami T, Kamada Y, Kato T, Uchida K, Nanmoku T, Obara N, Suzukawa K, Sanada M, Nakamura N, Aburatani H, Ogawa S, Chiba S. “Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice.” Blood Cancer J. 4:e264, 2014.

Sakata-Yanagimoto M +, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, Sakata S, Kamada Y, Nakamoto-Matsubara R, Tran NB, Izutsu K, Sato Y, Ohta Y, Furuta J, Shimizu S, Komeno T, Sato Y, Ito T, Noguchi M, Noguchi E, Sanada M, Chiba K, Tanaka H, Suzukawa K, Nanmoku T, Hasegawa Y, Nureki O, Miyano S, Nakamura N, Takeuchi K, Ogawa S, Chiba S. “Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.” Nat Genet. 46(2):171-5, 2014.





See Research Profile (External Site)


Advanced Hemato-Oncology Research